A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...

Considering the reasons behind the jump in licensing deal values, Chan added: “Licensing agreement deal values for mRNA-based ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent ...

Key developments in the health sector include Abbott's profit boost from medical sales, the UK's assisted dying law debate, Donald Trump's reproductive remarks, BAT's synthetic nicotine launch, ...

Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...

GSK filed two lawsuits at the US District of Delaware on 15 October saying that Moderna’s mRNA vaccine product Spikevax ...

The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...

The Boston Globe reports on findings from researchers at Mass General Brigham who examined "reservoirs" of the covid virus that hide inside people after their acute infections have ended. Also in the ...